SGLT2s beat DPP‑4 in cirrhosis

A nationwide analysis of Taiwan health records found that people with type 2 diabetes and established liver scarring who started an SGLT2-class diabetes medicine had lower rates of kidney failure, serious heart events, liver complications and death compared with people who started a DPP‑4–class drug. (jamanetwork.com) The study used Taiwan’s National Health Insurance Database and included 24,259 adults who began one of the two drug classes between 2016 and 2023, with a median follow-up of 2.3 years; 9,689 patients started an SGLT2 drug and 14,570 started a DPP‑4 drug, and the analysis was observational rather than randomized. (jamanetwork.com) SGLT2 drugs work by blocking the kidney protein that normally reabsorbs filtered glucose, which causes the body to excrete glucose and salt in the urine and produces downstream effects on blood pressure, weight and fluid balance; DPP‑4 drugs work by inhibiting an enzyme that breaks down gut-derived hormones that stimulate insulin, so they raise insulin only when blood sugar is high. (nature.com 1) (nature.com 2) The investigators used inverse probability of treatment weighting, a statistical technique that makes treated and comparison groups similar on measured baseline characteristics, to limit confounding from who was prescribed which drug. (jamanetwork.com) Measured effects were large for kidney and heart endpoints: compared with DPP‑4 users, SGLT2 use was associated with an adjusted hazard ratio of 0.34 for progression to end‑stage kidney disease (about a 66% lower rate), 0.66 for acute kidney injury (about 34% lower), and 0.67 for major adverse cardiovascular events (about 33% lower). (jamanetwork.com) The analysis also reported lower all‑cause mortality (hazard ratio 0.58) and fewer hepatic decompensation events (hazard ratio 0.65) among SGLT2 users in the primary Taiwanese cohort. (epocrates.com) Other real‑world datasets and pooled analyses have shown smaller but directionally similar liver and survival signals for SGLT2s versus DPP‑4s, and mechanistic reviews point to natriuresis (salt loss), reduced portal pressure, decreased liver fat and anti‑inflammatory effects as plausible pathways for hepatic benefit. (link.springer.com) (mdpi.com) The authors and commentators note key limitations — the study’s observational design cannot prove causation, the population is Taiwanese which may limit generalizability, and administrative data captured limited laboratory values and cirrhosis severity — so randomized trials or broader cohorts are needed to confirm these findings. (jamanetwork.com) (ajmc.com)